ATE556058T1 - 1-(2h)-isochinolonderivat - Google Patents

1-(2h)-isochinolonderivat

Info

Publication number
ATE556058T1
ATE556058T1 AT05709816T AT05709816T ATE556058T1 AT E556058 T1 ATE556058 T1 AT E556058T1 AT 05709816 T AT05709816 T AT 05709816T AT 05709816 T AT05709816 T AT 05709816T AT E556058 T1 ATE556058 T1 AT E556058T1
Authority
AT
Austria
Prior art keywords
substituted
hydrogen atom
group
atom
hetero ring
Prior art date
Application number
AT05709816T
Other languages
English (en)
Inventor
Kazuo Hattori
Satoshi Niizuma
Takehiro Okada
Hiroyuki Eda
Kenji Tatsuno
Miyuki Yoshida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE556058T1 publication Critical patent/ATE556058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05709816T 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat ATE556058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004030885 2004-02-06
PCT/JP2005/001764 WO2005075431A1 (ja) 2004-02-06 2005-02-07 １−（２ｈ）−イソキノロン誘導体

Publications (1)

Publication Number Publication Date
ATE556058T1 true ATE556058T1 (de) 2012-05-15

Family

ID=34836016

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05709816T ATE556058T1 (de) 2004-02-06 2005-02-07 1-(2h)-isochinolonderivat

Country Status (6)

Country Link
US (1) US8143274B2 (de)
EP (1) EP1724262B1 (de)
JP (1) JP4938311B2 (de)
AT (1) ATE556058T1 (de)
TW (1) TW200536830A (de)
WO (1) WO2005075431A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) * 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
TWI389897B (zh) * 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
US8410109B2 (en) * 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8034829B2 (en) * 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
JP5405314B2 (ja) * 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
US8735391B2 (en) * 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
US8420668B2 (en) 2008-11-28 2013-04-16 Chugai Seiyaku Kabushiki Kaisha 1-(2H)-isoquinolone derivative
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
DK2421533T3 (en) 2009-04-22 2019-01-07 Resverlogix Corp Hitherto unknown anti-inflammatory agents
WO2010127307A1 (en) * 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
CN101602725B (zh) * 2009-07-21 2012-07-11 浙江大学 六氢异喹啉酮类化合物的合成方法
AU2010305825A1 (en) * 2009-10-13 2012-04-19 Merck Sharp & Dohme B.V. Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor
FR2956816B1 (fr) * 2010-03-01 2012-05-18 Univ Joseph Fourier Utilisation de quinolones pour la preparation de medicaments, nouvelles quinolones et leur procede de synthese
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
EP2822656B1 (de) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituierte isochinolin-1-on-verbindungen und deren therapeutische anwendung
CA2868002C (en) 2012-03-21 2021-07-13 Rutgers, The State University Of New Jersey Antimicrobial agents
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
EP2970143B1 (de) 2013-03-15 2022-11-09 Johnson Matthey Public Limited Company Verfahren zur herstellung von alkylestern aus 4-(5-(bis(2-hydroxyethyl)amino)-1-methyl-1h-benzo[d-]imidazol-2-yl-)buttersäure
US9611223B2 (en) 2013-09-11 2017-04-04 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2015095446A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
TN2018000130A1 (en) 2015-11-06 2019-10-04 Neurocrine Biosciences Inc N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
US10513528B2 (en) 2016-02-25 2019-12-24 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
EP3590931A4 (de) * 2017-03-03 2020-11-18 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Amidderivatinhibitor und herstellungsverfahren und anwendung davon
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
EP3634953B1 (de) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Verbindungen zur behandlung von morbus huntington
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
WO2019232223A1 (en) 2018-05-30 2019-12-05 University Of Notre Dame Du Lac Hsp90 beta selective inhibitors
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
WO2021113478A1 (en) 2019-12-06 2021-06-10 Neurocrine Biosciences, Inc. Muscarinic receptor 4 antagonists and methods of use
GB2634228A (en) * 2023-10-02 2025-04-09 Duke Street Bio Ltd PARP1 inhibitor compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
EP1009404A4 (de) 1997-05-13 2009-07-01 Octamer Inc METHODEN ZUR BEHANDLUNG VON ENTZÜNDUNGEN ODER INFLAMMATIONS ERKRANKUNGEN DURCH INHIBITOREN DER pADPRT
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
WO2005075432A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用

Also Published As

Publication number Publication date
EP1724262B1 (de) 2012-05-02
EP1724262A1 (de) 2006-11-22
TW200536830A (en) 2005-11-16
JP4938311B2 (ja) 2012-05-23
US8143274B2 (en) 2012-03-27
JPWO2005075431A1 (ja) 2007-10-11
US20070185160A1 (en) 2007-08-09
WO2005075431A1 (ja) 2005-08-18
EP1724262A4 (de) 2009-10-21

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
EA200601235A1 (ru) Производные тиазола
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
WO2008114817A1 (ja) 新規なアデニン化合物
WO2008114819A1 (ja) 新規アデニン化合物
WO2008108386A1 (ja) 医薬組成物
SE0400284D0 (sv) Novel compounds
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
ATE532770T1 (de) Imidazolderivat
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20064297L (no) Aminoalkoholforbindelse
EP1634874A4 (de) Imidazolidinderivate
UY27803A1 (es) Derivados de benzoxazina y usos de los mismos.
EP1775289A4 (de) Neue imidazolidinderivate
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
TW200517387A (en) Compounds exhibiting thrombopoietin receptor agonism
EA200700997A1 (ru) 2,5- и 2,6-дизамещенные аналоги бензазола, полезные в качестве ингибиторов протеинкиназ
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
EA200700322A1 (ru) Оксазолидиноны, содержащие оксиндолы, в качестве антибактериальных агентов